Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M186Revenue (TTM) $M0.1Net Margin (%)-53,705.0Altman Z-Score-6.0
Enterprise Value $M141EPS (TTM) $-0.9Operating Margin %-59,693.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.5Pre-tax Margin (%)-53,704.0Higher ROA y-yN
Price/Book5.510-y EBITDA Growth Rate %-7.8Quick Ratio3.9Cash flow > EarningsY
Price/Sales1,3905-y EBITDA Growth Rate %-3.0Current Ratio3.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-75.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-114.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M66.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 2.78-27%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 2.78-53%New holding81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.4411.48view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0632.04view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.70.74view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.585.43view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.614.21view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.671.87view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.518.37view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.58.8view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-47.08view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-45.6view

Quarterly/Annual Reports about CYTR:

News about CYTR:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CYTRX CORP Financials May 19 2016
Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City May 12 2016
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition May 11 2016
CytRx reports 1Q loss May 11 2016
CytRx reports 1Q loss May 11 2016
CytRx Reports First Quarter 2016 Financial Results May 11 2016
CYTRX CORP Files SEC form 10-Q, Quarterly Report May 10 2016
CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail May 10 2016
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference Apr 28 2016
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference Apr 28 2016
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the... Apr 25 2016
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the... Apr 25 2016
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical... Apr 20 2016
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical... Apr 20 2016
3 Stocks With Catalysts That Could Capitalize on Biotech Momentum Apr 08 2016
ETF’s with exposure to CytRx Corp. : April 5, 2016 Apr 05 2016
CytRx Corp (CYTR) in Focus: Stock Rises 10.2% in Session Apr 05 2016
CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering... Apr 04 2016
CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering... Apr 04 2016
ETF’s with exposure to CytRx Corp. : March 23, 2016 Mar 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)